Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia

kozaburo akiyoshi, Suzan Dziennis, Julie Palmateer, Xuefang Ren, Arthur A. Vandenbark, Halina Offner, Paco S. Herson, Patricia D. Hurn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A key target for novel stroke therapy is the regulation of post-ischemic inflammatory mechanisms. Recent evidence emphasizes the role of T lymphocytes of differing subtypes in the evolution is ischemic brain damage. We have recently demonstrated the benefit of myelin antigen-specific immunodulatory agents known as recombinant T cell receptor ligands (RTLs) in a standard murine model of focal stroke. The aim of the current study was to extend this initial observation to RTL treatment in a therapeutically relevant timing after middle cerebral artery occlusion (MCAO) and verify functional benefit to complement histological outcome measures. We observed that the administration of mouse-specific RTL551 reduced infarct size and improved sensorimotor outcome when administered within a 3 h post-ischemic therapeutic window. RTL551 treatment reduced cortical, caudate putamen, and total infarct volume as compared to vehicle-treated mice. Using a standard behavioral testing repertoire, we observed that RTL551 reduced sensorimotor impairment 3 days after MCAO. Humanized RTL1000 (HLA-DR2 moiety linked to hMOG-35-55 peptide) also reduced infarct size in HLA-DR2 transgenic mice. These data indicate that this neuroantigen-specific immunomodulatory agent reduces damage when administered in a therapeutically relevant reperfusion timeframe.

Original languageEnglish
Pages (from-to)404-410
Number of pages7
JournalTranslational Stroke Research
Volume2
Issue number3
DOIs
Publication statusPublished - Sep 1 2011

Fingerprint

HLA-DR2 Antigen
Middle Cerebral Artery Infarction
T-Cell Antigen Receptor
Brain Ischemia
Stroke
Ligands
Putamen
Myelin Sheath
Transgenic Mice
Reperfusion
Observation
Outcome Assessment (Health Care)
T-Lymphocytes
Antigens
Peptides
Brain
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

akiyoshi, K., Dziennis, S., Palmateer, J., Ren, X., Vandenbark, A. A., Offner, H., ... Hurn, P. D. (2011). Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia. Translational Stroke Research, 2(3), 404-410. https://doi.org/10.1007/s12975-011-0085-1

Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia. / akiyoshi, kozaburo; Dziennis, Suzan; Palmateer, Julie; Ren, Xuefang; Vandenbark, Arthur A.; Offner, Halina; Herson, Paco S.; Hurn, Patricia D.

In: Translational Stroke Research, Vol. 2, No. 3, 01.09.2011, p. 404-410.

Research output: Contribution to journalArticle

akiyoshi, K, Dziennis, S, Palmateer, J, Ren, X, Vandenbark, AA, Offner, H, Herson, PS & Hurn, PD 2011, 'Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia', Translational Stroke Research, vol. 2, no. 3, pp. 404-410. https://doi.org/10.1007/s12975-011-0085-1
akiyoshi, kozaburo ; Dziennis, Suzan ; Palmateer, Julie ; Ren, Xuefang ; Vandenbark, Arthur A. ; Offner, Halina ; Herson, Paco S. ; Hurn, Patricia D. / Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia. In: Translational Stroke Research. 2011 ; Vol. 2, No. 3. pp. 404-410.
@article{a2031a6a7d78401d97d53bfff23c2d37,
title = "Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia",
abstract = "A key target for novel stroke therapy is the regulation of post-ischemic inflammatory mechanisms. Recent evidence emphasizes the role of T lymphocytes of differing subtypes in the evolution is ischemic brain damage. We have recently demonstrated the benefit of myelin antigen-specific immunodulatory agents known as recombinant T cell receptor ligands (RTLs) in a standard murine model of focal stroke. The aim of the current study was to extend this initial observation to RTL treatment in a therapeutically relevant timing after middle cerebral artery occlusion (MCAO) and verify functional benefit to complement histological outcome measures. We observed that the administration of mouse-specific RTL551 reduced infarct size and improved sensorimotor outcome when administered within a 3 h post-ischemic therapeutic window. RTL551 treatment reduced cortical, caudate putamen, and total infarct volume as compared to vehicle-treated mice. Using a standard behavioral testing repertoire, we observed that RTL551 reduced sensorimotor impairment 3 days after MCAO. Humanized RTL1000 (HLA-DR2 moiety linked to hMOG-35-55 peptide) also reduced infarct size in HLA-DR2 transgenic mice. These data indicate that this neuroantigen-specific immunomodulatory agent reduces damage when administered in a therapeutically relevant reperfusion timeframe.",
author = "kozaburo akiyoshi and Suzan Dziennis and Julie Palmateer and Xuefang Ren and Vandenbark, {Arthur A.} and Halina Offner and Herson, {Paco S.} and Hurn, {Patricia D.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1007/s12975-011-0085-1",
language = "English",
volume = "2",
pages = "404--410",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "3",

}

TY - JOUR

T1 - Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia

AU - akiyoshi, kozaburo

AU - Dziennis, Suzan

AU - Palmateer, Julie

AU - Ren, Xuefang

AU - Vandenbark, Arthur A.

AU - Offner, Halina

AU - Herson, Paco S.

AU - Hurn, Patricia D.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - A key target for novel stroke therapy is the regulation of post-ischemic inflammatory mechanisms. Recent evidence emphasizes the role of T lymphocytes of differing subtypes in the evolution is ischemic brain damage. We have recently demonstrated the benefit of myelin antigen-specific immunodulatory agents known as recombinant T cell receptor ligands (RTLs) in a standard murine model of focal stroke. The aim of the current study was to extend this initial observation to RTL treatment in a therapeutically relevant timing after middle cerebral artery occlusion (MCAO) and verify functional benefit to complement histological outcome measures. We observed that the administration of mouse-specific RTL551 reduced infarct size and improved sensorimotor outcome when administered within a 3 h post-ischemic therapeutic window. RTL551 treatment reduced cortical, caudate putamen, and total infarct volume as compared to vehicle-treated mice. Using a standard behavioral testing repertoire, we observed that RTL551 reduced sensorimotor impairment 3 days after MCAO. Humanized RTL1000 (HLA-DR2 moiety linked to hMOG-35-55 peptide) also reduced infarct size in HLA-DR2 transgenic mice. These data indicate that this neuroantigen-specific immunomodulatory agent reduces damage when administered in a therapeutically relevant reperfusion timeframe.

AB - A key target for novel stroke therapy is the regulation of post-ischemic inflammatory mechanisms. Recent evidence emphasizes the role of T lymphocytes of differing subtypes in the evolution is ischemic brain damage. We have recently demonstrated the benefit of myelin antigen-specific immunodulatory agents known as recombinant T cell receptor ligands (RTLs) in a standard murine model of focal stroke. The aim of the current study was to extend this initial observation to RTL treatment in a therapeutically relevant timing after middle cerebral artery occlusion (MCAO) and verify functional benefit to complement histological outcome measures. We observed that the administration of mouse-specific RTL551 reduced infarct size and improved sensorimotor outcome when administered within a 3 h post-ischemic therapeutic window. RTL551 treatment reduced cortical, caudate putamen, and total infarct volume as compared to vehicle-treated mice. Using a standard behavioral testing repertoire, we observed that RTL551 reduced sensorimotor impairment 3 days after MCAO. Humanized RTL1000 (HLA-DR2 moiety linked to hMOG-35-55 peptide) also reduced infarct size in HLA-DR2 transgenic mice. These data indicate that this neuroantigen-specific immunomodulatory agent reduces damage when administered in a therapeutically relevant reperfusion timeframe.

UR - http://www.scopus.com/inward/record.url?scp=80052268543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052268543&partnerID=8YFLogxK

U2 - 10.1007/s12975-011-0085-1

DO - 10.1007/s12975-011-0085-1

M3 - Article

C2 - 21961027

AN - SCOPUS:80052268543

VL - 2

SP - 404

EP - 410

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 3

ER -